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ABSTRACT
Introduction: A number of studies have established
that children, adolescents and adults with Asperger
syndrome (AS) and high functioning autism (HFA)
have significant problems with anxiety. Cognitive
behavioural therapy (CBT) is an effective treatment for
anxiety in a variety of clinical populations. There is a
growing interest in exploring the effectiveness of CBT
for people with AS who have mental health problems,
but currently there are no known clinical trials
involving adults with AS or HFA. Studies with children
who have AS have reported some success. The
current study aims to examine whether modified
group CBT for clinically significant anxiety in an AS
population is likely to be efficacious.
Methods and analysis: This study is a randomised,
single-blind crossover trial. At least 36 individuals will
be recruited and randomised into a treatment arm or a
waiting-list control arm. During treatment, individuals
will receive 3 sessions of individual CBT, followed by
21 sessions of group CBT. Primary outcome
measures focus on anxiety. Secondary outcome
measures focus on everyday social and psychiatric
functioning, additional measures of anxiety and fear,
depression, health-related quality of life and treatment
cost. Assessments will be administered at pregroup
and postgroup and at follow-up by researchers who
are blinded to group allocation. The trial aims to find
out whether or not psychological treatments for
anxiety can be adapted and used to successfully treat
the anxiety experienced by people with AS.
Furthermore, we aim to determine whether this
intervention represents good value for money.
Ethics and dissemination: The trial received a
favourable ethical opinion from a National Health
Service (NHS) Research Ethics Committee. All
participants provided written informed consent.
Findings will be shared with all trial participants, and
the general public, as well as the scientific
community.
Trial Registration: ISRCTN 30265294 (DOI:
10.1186/ISRCTN30265294), UKCRN 8370.
BACKGROUND
Anxiety-related symptomology is commonly
found in those with autistic spectrum disor-
ders (ASDs).1–4 Prevalence studies indicate
ARTICLE SUMMARY
Article focus
▪ People with autistic spectrum disorders have
higher rates of mental health problems than the
general population.
▪ The aims of this trial are (1) to develop group-
based cognitive behavioural therapy (CBT) for
people with Asperger syndrome and high func-
tioning autism who have anxiety disorders, (2)
to asssess the efficacy of the intervention
through a pilot, single-blind, crossover rando-
mised control trial and (3) to estimate the cost-
effectiveness of the CBT intervention compared
to no intervention.
Key messages
▪ This study is a pilot trial which will determine
whether or not group CBT is likely to be an
effective intervention for anxiety disorders
among people who have autistic spectrum
disorders.
▪ The trial will also determine whether the inter-
vention is cost-effective.
▪ The study will also examine the views partici-
pants have about the intervention.
Strengths and limitations of this study
▪ Appropriate randomisation and blinding have
been used.
▪ The study makes use of several different types of
clinical assessment methods.
▪ However, the sample size is relatively small, but
nevertheless should be sufficient, bearing in
mind that little is known about the effectiveness
of CBT for mental health problems among adults
with autistic spectrum disorders.
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that around 13.6% of children with Asperger syndrome
(AS) suffer from clinically relevant anxiety5 and up to
45% of adolescents with AS have signiﬁcant difﬁculties
with generalised anxiety, social anxiety or speciﬁc
phobias.6 A recent study found that in a sample of
young adults with AS, around 50% had an anxiety dis-
order,7 while other evidence suggests that people with
ASDs are quite likely to develop difﬁculties across a
range of anxiety disorders (eg, panic disorder and gen-
eralised anxiety disorder).8 9
Recent guidance creates standards for the diagnosis
and management of adults with ASDs,10 and while there
are an increasing number of adults being diagnosed
with ASDs, the National Health Service (NHS) in the
UK is charged with meeting the mental health needs of
this population. Although currently there are no known
data relating to the cost of AS and anxiety for the UK,
the lifetime cost of ASDs is thought to be in the region
of £2.4 million/person, with the total cost to the UK
society exceeding £1 billion/year.11 The weekly societal
cost of providing care to a person with an ASD in 1999–
2000 was estimated to be in the region of £855.00, with
an associated parental loss of income estimated to be in
the region of £275.00/week.12 In view of this, effective
treatments for anxiety in this population may lead to sig-
niﬁcant improvements in psychosocial functioning, inde-
pendence and quality of life.
Cognitive behavioural therapy (CBT) has been shown
to be an effective treatment for anxiety in people
without ASDs.13 14 As a consequence, there is a growing
interest in examining the utility of CBT for people with
ASDs who experience difﬁculties with anxiety. Adapted
CBT has been shown to be a successful treatment for
anxiety disorders among children with ASD.15–19
Cardaciotto and Herbert20 and Weiss and Lunsky21
undertook some case study work suggesting that CBT
may be helpful for adults with AS. In a recent rando-
mised controlled trial (RCT), mindfulness-based therapy
was found to reduce anxiety symptoms in adults with
ASD, although it is unclear whether or not the assessors
were blind within this study.22 At present, there appears
to be no published randomised, single-blind control
trials investigating the effectiveness of group CBT for
adults with ASD and anxiety disorders.
The government autism strategy, ‘fulﬁlling and reward-
ing lives’, recognises that children and adults with ASD
are excluded from many NHS services, including mental
healthcare.23 The current study aims to help achieve the
goals set within this strategy by contributing to the cre-
ation of a knowledge base. This will help inform clinical
practice and service delivery for the treatment of adults
with AS who experience problems with anxiety. In line
with the recommendations made by the National
Institute for Health and Care Excellence (NICE),10 it
will also examine whether CBT is cost-effective for the
treatment of anxiety among adults with ASD. Roberge
et al24 argue that group CBT is more cost-effective than
individual CBT in patients with some types of anxiety
disorders and a similar approach has been adopted
within the current study.
The key aims are (1) To develop a modiﬁed, group-
based CBT intervention manual for adults with AS and
clinical problems with anxiety; (2) to assess the efﬁcacy
of the CBT intervention through a pilot, single-blind,
crossover RCT in adults with AS experiencing problems
with anxiety and (3) to estimate the cost-effectiveness of
the CBT intervention compared with no intervention.
Assessment of efﬁcacy will include assessments of
anxiety and depression symptomology, as well as social
and occupational functioning.
METHOD
Design and randomisation
This study is a single-blind, randomised crossover trial.
Owing to the nature of the intervention, therapists and
participants cannot be blinded to treatment allocation.
However, researchers who carry out the assessments will
be blinded in order to minimise bias. Participants will
be allocated to the treatment arm (group CBT) or the
waiting-list control arm using block randomisation with
even pairs. The randomisation will be stratiﬁed by study
site. The therapists at each research site will contact par-
ticipants to inform them of their group allocation, while
blinded researchers will complete the assessments with
participants. All of the randomisation procedures are to
be completed by the Norfolk and Norwich University
Hospitals NHS Foundation Trust, Clinical Research and
Trials Unit based at the University of East Anglia.
After 24 weeks of treatment, the two arms will cross
over and those within the waiting-list control group will
receive 24 weeks of treatment, while those who have
already had treatment will be assessed again following
this second period of treatment. This will allow for a
6-month follow-up of 50% of the participants within the
trial.
Allocation concealment
Adequate allocation concealment will be ensured using
an onsite computer system with allocations kept in a
locked, unreadable computer ﬁle. Only the therapists
will access this after enrolled participants have been
entered into the computer system.
Implementation
Participants will go through a screening process con-
ducted by researchers. This will ensure that they meet
the inclusion criteria before they are enrolled into the
study. Randomisation will be computer generated. The
software written to enable randomisation will use a pro-
gramming system called VB.NET/ASP.NET and the
underlying database will be SQL Server 2005.
Blinding
At least three researchers will be blind to the randomisa-
tion process and group allocation. They will remain
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blind during the postgroup and follow-up assessments.
Participants will be regularly reminded not to disclose
their group allocation to these researchers throughout
their involvement in the study. All participants and the
therapists will be aware of the group allocation.
Participants
Thirty-six individuals will be recruited throughout Kent,
South East London and Norfolk within the UK.
Recruitment will be through learning disability teams,
Asperger/autism teams, AS user groups, such as
Asperger East Anglia, the Kent Autistic Trust, Bridging
the Gap, the Disability and Dyslexia Support Services at
the University of Kent, and adult mental health teams.
The inclusion criteria are: (1) participants fulﬁl diag-
nostic criteria for AS, high functioning autism or perva-
sive developmental disorder not speciﬁed; (2)
participants have clinically signiﬁcant difﬁculties with
anxiety as conﬁrmed through the use of the Hamilton
Rating Scale for Anxiety, with a score of >14 qualifying
for inclusion; (3) participants are between 16 and
65 years of age and (4) Full Scale Intelligence Quotient
>70. The exclusion criteria are (1) participants suffering
from post-traumatic stress disorder, or anxiety related to
substance misuse; (2) comorbid severe psychiatric disor-
ders that impair capacity to consent to take part (eg,
psychosis); and (3) current substance abuse, such as
alcohol or drugs.
Sample size
Bearing in mind that this is a pilot study, and consider-
ing that this study will not be a deﬁnitive RCT concern-
ing the clinical effectiveness of this intervention, a
sample size of 36 has been chosen. If we take the
Hamilton Anxiety Rating Scale as our primary outcome
measure, and consider that other trials of CBT for
anxiety disorder have reported between a 66% and 72%
change on this measure as a consequence of psycho-
logical treatment,25–27 then our study is likely to have a
large effect size. However, we do not know whether the
clinical effectiveness of group CBT is similar for people
with AS. Once this study is completed, we will be able to
estimate the sample size needed for a deﬁnitive trial.
Ethical considerations
Informed consent will be sought from participants and
their carers. Research workers are responsible for provid-
ing study information to participants and obtaining
consent; all participants are afforded time to consider
whether they wish to participate and are given the
opportunity to ask any questions. Information about the
study was provided in an ‘easier to read’ format for parti-
cipants who may have reading difﬁculties. Participants
may withdraw from the trial at any stage without giving a
reason. The withdrawal will not affect access to other
treatments or services. Participants will have the contact
details of the study team and are able to make contact
and ask any questions. Should they wish to do so,
participants who withdraw from the trial will be able to
complete the scheduled outcome assessments. All infor-
mation disclosed and data collected in the study will be
conﬁdential, and individuals will not be identiﬁable in
any published material. In line with standard operating
procedures, the reporting of serious adverse events will
be made to the Chief Investigator, who, together with
the study sponsor (Norfolk and Suffolk NHS Foundation
Trust), will follow national procedures for reporting
such incidents to the NHS ethics committee.
Intervention
The intervention used within this study comprises 24
weekly sessions, each lasting approximately 1 h. Those in
the treatment arm will receive three initial sessions of
1:1 CBT, followed by 21 group CBT sessions. The initial
three sessions of therapy will aim to help socialise each
participant into CBT and to address any concerns they
may have about joining the group.
In order to ensure adherence to treatment, a treat-
ment manual28 was developed with speciﬁc aims for
each session, and all sessions will be delivered by a regis-
tered clinical psychologist or a qualiﬁed cognitive behav-
ioural therapist. The treatment manual includes the
following topics (1) cognitive restructuring, (2) anxiety
management techniques, (3) systematic desensitisation,
(4) exposure to feared social situations and (4) social
skills training. Cognitive restructuring refers to the
process of learning to identify unhelpful cognitions,
which may trigger or maintain anxiety, and then learn-
ing to challenge or replace these cognitions with more
appropriate appraisals. Anxiety management techniques
refer to progressive relaxation training, learning to iden-
tify anxiety-related triggers and the development of
appropriate techniques to successfully manage anxiety.
Systematic desensitisation and exposure to feared social
situations involve the gradual exposure of the participant
in a safe manner to social situations that provoke fear.
These techniques allow participants to learn that anxiety
is not harmful and help to reduce avoidance to feared
situations. Finally, social skills training refers to the
actual teaching of social skills including how to under-
stand verbal and non-verbal social cues, and appropriate
social interaction across contexts. These skills will be
practiced in vivo. In addition to the intervention, partici-
pants in both arms before and after crossover were per-
mitted to engage in treatment as usual (TAU).
Outcome measures and analysis
All outcome measures will be administered by the
researchers at baseline (prior to any treatment), after
week 24 (follow-up 1) and after week 52 (follow-up 2).
Besides the primary and secondary measures at baseline,
we will record individual demographics, which includes
their age, gender, ethnic group, diagnostic history,
current medication and any prior treatment.
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Primary outcome measures
Social phobia inventory
This is a 17-item self-report measure of behavioural,
physiological and cognitive symptoms associated with
social phobia.29 Participants will rate the frequency with
which they experience each symptom over the past
week, using a ﬁve-point Likert-type scale (0–4).
Liebowitz social anxiety scale
This instrument is a self-report scale that assesses fear
and avoidance throughout 24 listed situations, which are
likely to elicit social anxiety.30
Hamilton rating scale for anxiety
This is a structured clinician-rated scale incorporating 14
factors, which will be considered as valid indicators of
anxiety.31 Each factor reﬂects a symptom of anxiety;
physical as well as mental symptoms are represented.
The factors are scored on a ﬁve-point scale as part of a
structured interview.
Secondary outcome measures
Social and emotional functioning interview (informant and
subject versions)
A semistructured clinician-rated assessment of everyday
social and psychiatric functioning will be conducted,
which is designed to assess independence, leisure, inter-
personal problems, employment and social relationships.
Some items are shared with the Autistic Diagnostic
Observation Schedule.32
Social Interaction Anxiety Scale
This self-report 20-item scale is a measure of anxiety
associated with social anxiety and social phobia in
accordance with the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) criteria.33 34
Experiences will be rated on a ﬁve-point scale from 0
(not at all characteristic of me) to 4 (extremely charac-
teristic of me).
Fear questionnaire
This is a self-report questionnaire about individual per-
ception of fears and phobias in which respondents will
be asked what will be the likelihood of their avoiding a
list of situations, due to anxiety/fear or any other
unpleasant feelings. In addition to the 15 pre-existing
items, the individual will be asked to document and
score any individual phobias they would wish to be
treated.35
Hamilton rating scale for depression
This structured clinician-rated interview is considered a
valid indicator of depression and the ratings will be
based on the interviewer’s objective and subjective per-
ceptions during the assessment.36 Eight items are scored
on a 0 (not present) to 4 (severe) point scale, and nine
items are scored from 0 to 2 (levels of severity).
SF-36 (http://www.sf-36.org) and EQ-5D (http://www.
euroqol.org)
These two self-report instruments will be used to assess
overall health-related quality of life (HRQoL). Summary
scores from the SF-36 and EQ-5D questionnaires will be
used to estimate health proﬁles as well as an index of
overall HRQoL (utility) using standard algorithms rele-
vant to the UK population.37 38
Resource use and cost
Health service use, patient’s out-of-pocket costs and the
value of any lost productivity to society will be collected
using an adapted version of the client service receipt
inventory. This is a tool speciﬁcally designed to measure
patient resource use in the area of mental health,
although it has subsequently been adapted to other
areas too. Resource use involved in delivering the inter-
vention (ie, conducting the group-based sessions) will be
based on time records for professionals and participants.
Resource use estimates will be multiplied by unit costs of
services extracted from standard NHS sources (eg, unit
costs of health and social care39 and National Schedule
of Reference Costs40). Where national estimates are not
available, attempts will be made to obtain representative
local or regional unit costs. A common price-year will be
used throughout to be determined at the point of ana-
lysis. As the follow-up period for this trial is less than
1 year, discounting of costs or outcomes is not necessary.
Statistical methods
Data will be analysed using repeated measures statistics
(eg, repeated measures analysis of variance and analysis
of covariance) making use of intent-to-treat analysis as
appropriate. We may wish to control for various variables
in this analysis, for example differences in baseline
anxiety scores. Summary scores from the SF-36 and
EQ-5D questionnaires will be used to estimate health pro-
ﬁles as well as an index of overall HRQoL (utility). SF-36
and EQ-5D results will be converted to utilities using the
SF-6D37 and multiview harmonium38 algorithms, respect-
ively. Quality-adjusted life years (QALYs) gained will be
estimated from the resulting area under the curves.
Collection of SF-36 and EQ-5D will allow a comparison
of the performance of the two instruments in this pilot
study to update data collection tools for future full trials.
Costs will be analysed from the perspectives of the public
sector (NHS and social services) and society, and based
on the resource use gleaned from the resource use ques-
tionnaire multiplied by unit costs as described above.
Within-trial economic analyses will report the mean
cost and outcome, incremental cost and outcome and
incremental cost-effectiveness ratios (ICERs) over a time
horizon of 24 weeks (ie, comparing approximately
6 months of group CBT vs 6 months of ‘TAU’).
Outcomes in the economic analysis will be the Social
and Emotional Functioning Interview score and QALYs
gained (estimated using the EQ-5D and SF-6D algo-
rithms). Uncertainty around the point estimate of the
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ICER will be presented as a cost-effectiveness acceptabil-
ity curve.41 Additional modelling analyses will extend
the time horizon to 5 years based on the extrapolation
of trial costs and outcomes to the longer time horizon
(and making use of the 24-week follow-up data in the
intervention arm). Different assumptions as to the dur-
ation of effectiveness of treatment will be compared in a
series of scenario analyses.
DISCUSSION
Recently published NICE guidelines10 call for greater
support and service planning for those with ASDs.
Despite the high prevalence of anxiety in this popula-
tion, there are few studies investigating appropriate
intervention. This study aims to investigate the efﬁcacy
of CBT for anxiety in adults with ASDs.
This study will involve developing and trialling modi-
ﬁed group CBT speciﬁcally for adults with ASDs experi-
encing problems with anxiety. The use of CBT may lead
to a reduction in anxiety and an increase in social and
occupational functioning among adults with ASDs. The
study will also investigate whether the use of group CBT
is a cost-effective approach in treating anxiety in this
population. This is not a deﬁnitive trial, and although
we aim to determine whether or not CBT is likely to be
effective, once treatment is completed, participants will
be invited to take part in further interviews in order to
ascertain their personal views about the intervention.
Trial status
The trial is currently closed to recruitment, and all sites
have crossed over. Data collection is scheduled to ﬁnish
in January 2014.
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